119 related articles for article (PubMed ID: 11258518)
1. An efficient batch preparation of high specific activity.
Amartey JK; Al-Jammaz I; Lambrecht RM
Appl Radiat Isot; 2001 May; 54(5):711-4. PubMed ID: 11258518
[TBL] [Abstract][Full Text] [Related]
2. Establishment of a fast and high yield method for routine production of [(131) I]MIBG and investigation of its radiochemical stability for diagnosis and treatment uses.
Davarpanah MR; Attar Nosrati S; Khoshhosn HA; Fazlali M; Kazemi Boudani M
J Labelled Comp Radiopharm; 2013 Nov; 56(13):686-8. PubMed ID: 25196031
[TBL] [Abstract][Full Text] [Related]
3. A convenient method for the preparation of radioiodinated meta-iodobenzylguanidine at a no-carrier-added level.
Wang G; Chen Z; Wu E; Wang Y; Huang H
J Labelled Comp Radiopharm; 2015; 58(11-12):442-4. PubMed ID: 26391308
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of radioiodination of meta-iodobenzylguanidine (MIBG) catalysed by in situ generated Cu(I) and directly added Cu(II).
Prabhakar G; Mehra KS; Ramamoorthy N; Chattopadhyay S; Oommen R; Narasimhan S; Nair NA; Gunasekaran S
Appl Radiat Isot; 1999 Jun; 50(6):1011-4. PubMed ID: 10355103
[TBL] [Abstract][Full Text] [Related]
5. A convenient solution-phase method for the preparation of meta-iodobenzylguanidine in high effective specific activity.
Donovan AC; Valliant JF
Nucl Med Biol; 2008 Oct; 35(7):741-6. PubMed ID: 18848658
[TBL] [Abstract][Full Text] [Related]
6. [A simple and rapid routine preparation of no-carrier added meta-I-123- and I-131-iodobenzylguanidine (I-123-MIBG and I-131-MIBG) for clinical nuclear medicine applications].
Samnick S; Kirsch CM
Nuklearmedizin; 1999; 38(7):292-6. PubMed ID: 10599069
[TBL] [Abstract][Full Text] [Related]
7. Updating the procedure for metaiodobenzylguanidine labelling with iodine radioisotopes employed in industrial production.
Franceschini R; Mosca R; Bonino C
J Nucl Biol Med (1991); 1991; 35(4):183-5. PubMed ID: 1823814
[TBL] [Abstract][Full Text] [Related]
8. Efficient production of therapeutic doses of [131I]-metaiodobenzylguanidine for clinical use.
Prabhakar G; Mathur A; Shunmugam G; Teje YD; Sachdev SS; Sivaprasad N
Appl Radiat Isot; 2011 Jan; 69(1):63-7. PubMed ID: 20933432
[TBL] [Abstract][Full Text] [Related]
9. Comparison of high-specific-activity ultratrace 123/131I-MIBG and carrier-added 123/131I-MIBG on efficacy, pharmacokinetics, and tissue distribution.
Barrett JA; Joyal JL; Hillier SM; Maresca KP; Femia FJ; Kronauge JF; Boyd M; Mairs RJ; Babich JW
Cancer Biother Radiopharm; 2010 Jun; 25(3):299-308. PubMed ID: 20578835
[TBL] [Abstract][Full Text] [Related]
10. No-carrier-added synthesis of a 4-methyl-substituted meta-iodobenzylguanidine analogue.
Vaidyanathan G; Affleck DJ; Zalutsky MR
Appl Radiat Isot; 2005 Mar; 62(3):435-40. PubMed ID: 15607920
[TBL] [Abstract][Full Text] [Related]
11. A rapid and efficient preparation of [123I]radiopharmaceuticals using a small HPLC (Rocket) column.
Katsifis A; Papazian V; Jackson T; Loc'h C
Appl Radiat Isot; 2006 Jan; 64(1):27-31. PubMed ID: 16129607
[TBL] [Abstract][Full Text] [Related]
12. A kit method for the high level synthesis of [211At]MABG.
Vaidyanathan G; Affleck DJ; Alston KL; Zhao XG; Hens M; Hunter DH; Babich J; Zalutsky MR
Bioorg Med Chem; 2007 May; 15(10):3430-6. PubMed ID: 17387017
[TBL] [Abstract][Full Text] [Related]
13. Synthesis of ring- and side-chain-substituted m-iodobenzylguanidine analogues.
Vaidyanathan G; Shankar S; Zalutsky MR
Bioconjug Chem; 2001; 12(5):786-97. PubMed ID: 11562197
[TBL] [Abstract][Full Text] [Related]
14. A hybrid solid-fluorous phase radioiodination and purification platform.
Dzandzi JP; Vera DR; Valliant JF
J Labelled Comp Radiopharm; 2014 Jul; 57(9):551-7. PubMed ID: 25069901
[TBL] [Abstract][Full Text] [Related]
15. Ten years of experience with MIBG applications and the potential of new radiolabeled peptides: a personal overview and concluding remarks.
Shapiro B
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):150-5. PubMed ID: 9002776
[TBL] [Abstract][Full Text] [Related]
16. Improved labelling of no-carrier-added 123I-MIBG and preliminary clinical evaluation in patients with ventricular arrhythmias.
Samnick S; Bader JB; Müller M; Chapot C; Richter S; Schaefer A; Sax B; Kirsch CM
Nucl Med Commun; 1999 Jun; 20(6):537-45. PubMed ID: 10451866
[TBL] [Abstract][Full Text] [Related]
17. A novel route to radioiodinated [123I]-N-succinimidyl-3-iodobenzoate, a reagent for radioiodination of bioactive peptides.
Al-Jammaz I; Al-Otaibi B; Amartey JK
Appl Radiat Isot; 2002 Nov; 57(5):743-7. PubMed ID: 12433050
[TBL] [Abstract][Full Text] [Related]
18. 99mTc-labeled MIBG derivatives: novel 99mTc complexes as myocardial imaging agents for sympathetic neurons.
Zhuang ZP; Kung MP; Mu M; Hou C; Kung HF
Bioconjug Chem; 1999; 10(2):159-68. PubMed ID: 10077463
[TBL] [Abstract][Full Text] [Related]
19. Iodopyridine-for-iodobenzene substitution for use with low molecular weight radiopharmaceuticals: application to m-iodobenzylguanidine.
Vaidyanathan G; Zalutsky MR; DeGrado TR
Bioconjug Chem; 1998; 9(6):758-64. PubMed ID: 9815170
[TBL] [Abstract][Full Text] [Related]
20. 124I-MIBG: a new promising positron-emitting radiopharmaceutical for the evaluation of neuroblastoma.
Cistaro A; Quartuccio N; Caobelli F; Piccardo A; Paratore R; Coppolino P; Sperandeo A; Arnone G; Ficola U
Nucl Med Rev Cent East Eur; 2015; 18(2):102-6. PubMed ID: 26315872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
